Nothing Special   »   [go: up one dir, main page]

SI3538528T1 - Pirol amidi kot alfa v integrin inhibitorji - Google Patents

Pirol amidi kot alfa v integrin inhibitorji

Info

Publication number
SI3538528T1
SI3538528T1 SI201730618T SI201730618T SI3538528T1 SI 3538528 T1 SI3538528 T1 SI 3538528T1 SI 201730618 T SI201730618 T SI 201730618T SI 201730618 T SI201730618 T SI 201730618T SI 3538528 T1 SI3538528 T1 SI 3538528T1
Authority
SI
Slovenia
Prior art keywords
alpha
integrin inhibitors
pyrrole amides
pyrrole
amides
Prior art date
Application number
SI201730618T
Other languages
English (en)
Inventor
Guohua Zhao
James Mignone
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of SI3538528T1 publication Critical patent/SI3538528T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
SI201730618T 2016-11-08 2017-11-07 Pirol amidi kot alfa v integrin inhibitorji SI3538528T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662418833P 2016-11-08 2016-11-08
EP17801236.5A EP3538528B1 (en) 2016-11-08 2017-11-07 Pyrrole amides as alpha v integrin inhibitors
PCT/US2017/060392 WO2018089360A1 (en) 2016-11-08 2017-11-07 Pyrrole amides as alpha v integrin inhibitors

Publications (1)

Publication Number Publication Date
SI3538528T1 true SI3538528T1 (sl) 2021-03-31

Family

ID=60409438

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201730618T SI3538528T1 (sl) 2016-11-08 2017-11-07 Pirol amidi kot alfa v integrin inhibitorji

Country Status (23)

Country Link
US (1) US10717736B2 (sl)
EP (1) EP3538528B1 (sl)
JP (1) JP7220653B2 (sl)
KR (1) KR102515507B1 (sl)
CN (1) CN110139864B (sl)
AU (1) AU2017359030A1 (sl)
BR (1) BR112019009293A2 (sl)
CA (1) CA3042693A1 (sl)
CY (1) CY1123893T1 (sl)
DK (1) DK3538528T3 (sl)
EA (1) EA201991124A1 (sl)
ES (1) ES2852351T3 (sl)
HR (1) HRP20210228T1 (sl)
HU (1) HUE053620T2 (sl)
IL (1) IL266469A (sl)
LT (1) LT3538528T (sl)
MX (1) MX377293B (sl)
PL (1) PL3538528T3 (sl)
PT (1) PT3538528T (sl)
RS (1) RS61453B1 (sl)
SI (1) SI3538528T1 (sl)
SM (1) SMT202100089T1 (sl)
WO (1) WO2018089360A1 (sl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10604520B2 (en) 2016-09-07 2020-03-31 Pliant Therapeutics, Inc. N-acyl amino acid compounds and methods of use
MX377359B (es) * 2016-11-08 2025-03-10 Bristol Myers Squibb Co Compuestos mono y espirocíclicos que continen ciclobutano y azetidina como inhibidores de la integrina alfa v.
MX2019007797A (es) 2016-12-29 2019-10-21 Univ Saint Louis Antagonistas de integrinas.
WO2018160521A2 (en) 2017-02-28 2018-09-07 Lazuli, Inc. Inhibitors of (alpha-v)(beta-6) integrin
MA52117A (fr) 2017-02-28 2022-04-06 Morphic Therapeutic Inc Inhibiteurs de l'intégrine (alpha-v) (bêta-6)
EP3843727A4 (en) * 2018-08-29 2022-08-17 Morphic Therapeutic, Inc. INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN
MA51066A (fr) 2018-08-29 2020-10-14 Morphic Therapeutic Inc Inhibiteurs d'intégrine
CN112969700B (zh) 2018-10-30 2024-08-20 吉利德科学公司 作为α4β7整合素抑制剂的咪唑并吡啶衍生物
US20220119383A1 (en) 2018-10-30 2022-04-21 Gilead Sciences, Inc. Quinoline derivatives as alpha4beta7 integrin inhibitors
EP3873605B1 (en) 2018-10-30 2024-10-23 Gilead Sciences, Inc. Compounds for inhibition of alpha4beta7 integrin
JP7189368B2 (ja) 2018-10-30 2022-12-13 ギリアード サイエンシーズ， インコーポレイテッド アルファ４ベータ７インテグリンの阻害のための化合物
CA3148613A1 (en) 2019-08-14 2021-02-18 Gilead Sciences, Inc. Phenylalanine derived compounds and their use as inhinitors of alpha 4 beta 7 integrin

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849736A (en) 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
IL118325A0 (en) * 1995-05-25 1996-10-31 Pont Merck And Pharmaceutical Integrin receptor antagonists and pharmaceutical compositions containing them
ZA972195B (en) 1996-03-15 1998-09-14 Du Pont Merck Pharma Spirocycle integrin inhibitors
IL136267A0 (en) 1997-11-26 2001-05-20 Du Pont Pharm Co 1,3,4-THIADIZOLES AND 1,3,4-OXADIAZOLES AS αVβ3 ANTAGONISTS
CA2315370A1 (en) 1997-12-17 1999-06-24 Merck & Co., Inc. Integrin receptor antagonists
TWI247008B (en) * 1998-04-10 2006-01-11 Searle & Co Heterocyclic glycyl beta-alanine derivatives
JP2002522540A (ja) 1998-08-13 2002-07-23 メルク エンド カムパニー インコーポレーテッド インテグリン受容体拮抗薬
AUPP646598A0 (en) 1998-10-12 1998-11-05 Fujisawa Pharmaceutical Co., Ltd. New processes for producing alpha-alanine derivative
DE19939981A1 (de) * 1999-08-24 2001-03-01 Merck Patent Gmbh Neue Inhibitoren des Integrins alphavß3
AU777919B2 (en) * 1999-11-08 2004-11-04 Merck Sharp & Dohme Corp. Process and intermediates for the preparation of imidazolidinone alpha V integrin antagonists
GB0001447D0 (en) * 2000-01-21 2000-03-08 Novartis Ag Organic compounds
WO2002060438A1 (en) 2001-01-29 2002-08-08 3-Dimensional Pharmaceuticals, Inc. Substituted indoles and their use as integrin antagonists
DK1539739T3 (da) * 2002-08-16 2011-03-07 Janssen Pharmaceutica Nv Piperidinylforbindelser, der selektivt binder integriner
TW200526626A (en) 2003-09-13 2005-08-16 Astrazeneca Ab Chemical compounds
MXPA06003477A (es) * 2003-10-01 2006-06-05 Merck Patent Gmbh Uso terapuetico de antagonistas de alfavbeta3 y alfavbeta6 integrinas como agentes antifibroticos.
WO2006108040A1 (en) 2005-04-05 2006-10-12 Janssen Pharmaceutica, N.V. Substituted indoles and their use as integrin antagonists
WO2007141473A1 (en) 2006-06-09 2007-12-13 Astrazeneca Ab N-(benzoyl)-o- [2- (pyridin- 2 -ylamino) ethyl] -l-tyrosine derivatives and related compounds as a5b1 antagonists for the treatment of solid tumors
WO2008125811A1 (en) 2007-04-11 2008-10-23 Astrazeneca Ab N-[HETEROARYLCARBONYL]-S-THIENYL-L-ALANINE DERIVATIVES AS α5β1 ANTAGONISTS
US8481549B2 (en) * 2010-01-19 2013-07-09 Theravance, Inc. Dual-acting thiophene, pyrrole, thiazole and furan antihypertensive agents
ITFI20100019A1 (it) 2010-02-12 2011-08-13 Univ Firenze Inibitori peptidomimetici di integrine basati sull'1,2,3-triazolo per la diagnosi e terapia dei tumori.
CN103038229B (zh) 2010-05-26 2016-05-11 桑诺维恩药品公司 杂芳基化合物及其使用方法
US9518053B2 (en) * 2013-02-07 2016-12-13 Scifluor Life Sciences, Inc. Fluorinated integrin antagonists
GB201305668D0 (en) * 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
TWI667233B (zh) 2013-12-19 2019-08-01 德商拜耳製藥公司 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
GB201417002D0 (en) * 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound
GB201417094D0 (en) * 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417011D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417018D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
EP3925959A1 (en) 2015-02-19 2021-12-22 OcuTerra Therapeutics, Inc. Fluorinated derivatives of 3-(2-oxo-3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)imidazolidin-1-yl)propanoic acid and uses thereof
JP2018515424A (ja) 2015-03-10 2018-06-14 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 抗アルファｖベータ１インテグリン阻害剤及び使用方法

Also Published As

Publication number Publication date
HUE053620T2 (hu) 2021-07-28
EA201991124A1 (ru) 2019-10-31
AU2017359030A1 (en) 2019-06-20
BR112019009293A2 (pt) 2019-07-30
LT3538528T (lt) 2021-03-10
JP7220653B2 (ja) 2023-02-10
SMT202100089T1 (it) 2021-03-15
EP3538528B1 (en) 2020-12-23
PL3538528T3 (pl) 2021-05-31
US10717736B2 (en) 2020-07-21
MX2019005233A (es) 2019-08-12
JP2020500182A (ja) 2020-01-09
CY1123893T1 (el) 2022-05-27
RS61453B1 (sr) 2021-03-31
DK3538528T3 (da) 2021-02-15
KR20190076031A (ko) 2019-07-01
PT3538528T (pt) 2021-02-16
HRP20210228T1 (hr) 2021-03-19
ES2852351T3 (es) 2021-09-13
EP3538528A1 (en) 2019-09-18
CN110139864A (zh) 2019-08-16
CN110139864B (zh) 2022-08-23
US20190256512A1 (en) 2019-08-22
CA3042693A1 (en) 2018-05-17
IL266469A (en) 2019-07-31
KR102515507B1 (ko) 2023-03-28
MX377293B (es) 2025-03-07
WO2018089360A1 (en) 2018-05-17

Similar Documents

Publication Publication Date Title
IL266469A (en) Pyrrol-amides as alpha-v-integrin inhibitors
ZA201905811B (en) Novel inhibitors
IL266470A (en) Monocyclic and spirocyclic compounds containing cyclobutane and aztidine as alpha-v-integrin inhibitors
IL255246A0 (en) Heterocyclic amides as kinase inhibitors
IL258180B (en) Heterocyclic compounds and their uses
GB201605126D0 (en) Inhibitors and their uses
IL266465A (en) Azole amides and amines as alpha five integrin inhibitors
IL246987A0 (en) Heteroaryl amides, preparations containing it and their uses
IL272649A (en) AHR inhibitors and their uses
SG11201708027XA (en) Compounds and their use as bace1 inhibitors
IL274425A (en) Pyrrolopyrazine derivatives as alpha five integrin inhibitors
IL275375A (en) Pyrrolidine amides II are converted
IL275374A (en) Pyrrolidine amides I are converted
IL254916A0 (en) Inhibitors and their uses
IL262400A (en) Erbb inhibitors and uses thereof
ZA201907136B (en) Ip6k inhibitors
IL251077B (en) Integrin inhibitors and their use
IL258870A (en) Substituted indazole compounds as rorgammat inhibitors and uses thereof
PL3209743T3 (pl) Zastosowanie foliowych materiałów licowych do polimerowego opakowania
IL251078B (en) Integrin inhibitors and their use
IL274550A (en) Dopamine-B-hydroxylase inhibitors
IL261644A (en) Oxalyl derivatives and their use as cyclophilin inhibitors
GB201721465D0 (en) Inhibitors
GB201720189D0 (en) Dopamine-B-hydroxylase inhibitors
GB201505975D0 (en) Inhibitors and their uses